Wave Life Sciences (WVE) pipeline and stated timing

Name in SEC filings: Wave Life Sciences, Inc.

Pipeline at a glance

Program	Event	Stage	Stated timing	Filing
WVE-006	/data readout	Stage not stated	the second half of 2026	10-Q · Jul 30, 2026
WVE-007	Topline/data readout	Phase 1	the second half of 2026	10-Q · Jul 30, 2026

Source: ORION, orionbiotechai.com/company/WVE, data as of Oct 18, 2026
https://www.orionbiotechai.com/company/WVE

Nearest upcoming stated timing: WVE-006 · Topline/data readout · the second half of 2026

SEC sources last checked Oct 18, 2026.

Programs and stated timing

○ Quote matched to filing (not yet reviewed by founder) · ✓ Checked by founder.

WVE-006

Matched

Topline/data readoutthe second half of 2026

Stage: Not stated

Public float: $851,013,538 · as of Jun 30, 2025 · SEC filing

We expect to share data from the 600 mg monthly multidose cohort of RestorAATion-2 in the second half of 2026.

10-Q · Filed Jul 30, 2026 · Last checked Oct 18, 2026

Source details

Accession 0001193125-26-324949

Alert me · Calendar: same stage and window-end month (2026-12)

WVE-007

Matched

Topline/data readoutthe second half of 2026

Stage: Phase 1SEC filing · “Phase 1”

Public float: $851,013,538 · as of Jun 30, 2025 · SEC filing

Additional data from the INLIGHT trial, including data from the 600 mg Phase 1 SAD cohort, are expected in the second half of 2026.

10-Q · Filed Jul 30, 2026 · Last checked Oct 18, 2026

Source details

Accession 0001193125-26-324949

Alert me · Calendar: same stage and window-end month (2026-12)

How this date was described over time

Company periods and sentences are quoted as written. A matching disclosure uses the SEC filing date for the same program and event type. As of Oct 19, 2026.

Program / event	Stated period and SEC wording	Disclosure in stated period
WVE-006Clinical results	the second half of 2026 “We expect to share data from the 600 mg monthly multidose cohort of RestorAATion-2 in the second half of 2026.” Filed Jul 30, 2026 · 10-Q	Still within period As of Oct 19, 2026
WVE-007Clinical results	the second half of 2026 “Additional data from the INLIGHT trial, including data from the 600 mg Phase 1 SAD cohort, are expected in the second half of 2026.” Filed Jul 30, 2026 · 10-Q	Still within period As of Oct 19, 2026
WVE-006Clinical results	the second half of 2026 “Wave expects to share data from the 600 mg (monthly) multidose cohort in the second half of 2026.” Filed May 18, 2026 · EX-99.1	Still within period As of Oct 19, 2026
WVE-006Clinical results	the second half of 2026 “We also expect to share data from the 600 mg multidose cohort in the second half of 2026.” Filed Apr 28, 2026 · 10-Q	Still within period As of Oct 19, 2026
WVE-006Clinical results	the second half of 2026 “Wave also expects to share data from the 600 mg multidose cohort in the second half of 2026.” Filed Apr 28, 2026 · EX-99.1	Still within period As of Oct 19, 2026

“Not compared” means ORION has not matched this wording against a complete set of SEC filings for its period. It says nothing either way about whether a matching filing exists. Wording without exact dates is not given calendar dates.

Watch WVE

Or email ORION to ask for this Watch.

Request another SEC timing statement

Suggest an SEC timing statement to add for WVE. You can include the original filing link in your note. The founder reads each request by hand.

Or email ORION.

Reading these records

First stated window: The timing wording in the earliest company statement located within the sources checked, quoted as written (for example “2H 2026”). An earlier statement may exist outside those sources.
Disclosure date: The date of the filing or company release that disclosed the readout. “None found” means no such disclosure was located in the sources checked. SEC filings were searched through the “SEC filings searched through” date shown.
1H, 2H, 1Q–4Q: First or second half, or first to fourth quarter, of the year named, as the company wrote it. Equivalent notations are compared together; the original wording stays visible.
SEC original: The filing as published on the SEC EDGAR system. “Company original” is the release on the company's own investor site.
Status: One of seven labels set by founder review of the original filings. Definitions: Methodology.

See WVE in the calendar · Review labels and methodology